Biosimilar Tracking Still Possible With Shared Medicare Codes, Woodcock Suggests
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA and CMS are working on a way to address pharmacovigilance through code modifiers, CDER director tells Senate panel.
You may also be interested in...
FDA Biosimilar Education Campaign Will Need To Be Targeted
Sen. Cassidy does not think additional appropriations are needed for a massive provider and patient education on biosimilars.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.